Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27187 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Nour Moukalled und 18 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
In the 2022 European LeukemiaNet classification, patients with nucleophosmin 1 (NPM1) ‐mutated acute myeloid leukemia (AML) were classified in the adverse‐risk category in the presence of high‐risk cytogenetics (CG). Nonetheless, the impact of various CG aberrations on posttransplant outcomes remains to be unraveled. This registry study analyzed adult patients with NPM1 ‐mutated de novo AML who underwent their first allogeneic hematopoietic cell transplantation in the first complete remission from 2005 to 2021. A total of 3275 patients were identified, 2782 had normal karyotype, 493 had chromosomal aberrations including 160 with adverse‐risk CG, 72 patients had complex karyotype (CK), and 66 monosomal karyotype (MK). Overall, 2377 (73%) patients had FLT3 ‐ITD. On univariate analysis, only FLT3 ‐ITD, minimal/measurable residual disease (MRD) positivity and CK, but not abnormal CG, affected posttransplant outcomes. On multivariable analysis, CK was associated with lower overall survival (OS) (hazard ratio [HR] 1.72, p = .009). In the subgroup of 493 patients with aberrant CG, the 2‐year leukemia‐free survival (LFS) and OS were around 61% and 68%, respectively. On multivariable analysis for this subgroup, CK and MRD positivity were associated with increased risk of relapse (HR 1.7, p = .025; and 1.99, p = .003 respectively) and worse LFS (HR 1.62, p = .018; and 1.64, p = .011 respectively) while FLT3‐ ITD, MK, or other CG abnormalities had no significant effect. Importantly, CK negatively affected OS (HR 1.91, p = .002). In the first complete remission transplant setting, CK was found as the only cytogenetic risk factor for worse outcomes in NPM1 ‐mutated AML. Nevertheless, even for this subgroup, a significant proportion of patients can achieve long‐term posttransplant survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
- EBMT Statistical Unit, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Sorbonne University, Paris, France.
- Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Hematology - BMT, Hopital St. Louis, Paris, France.
- Programme de Transplantation & Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
- Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Ali Bazarbachi
Zitieren
APA
Moukalled, N., Labopin, M., Versluis, J., Socié, G., Blaise, D., Salmenniemi, U., Rambaldi, A., Gedde-Dahl, T., Tholouli, E., Kröger, N., Bourhis, J. H., Von Dem Borne, P., Daguindau, E., Forcade, E., Nagler, A., Esteve, J., Ciceri, F., Bazarbachi, A., & Mohty, M. (2024). Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. American Journal of Hematology. https://doi.org/10.1002/ajh.27187
Vancouver
Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, et al. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. American Journal of Hematology. 2024. doi:10.1002/ajh.27187
BibTeX
@article{Moukalled2024,
author = {Moukalled, Nour and Labopin, Myriam and Versluis, Jurjen and Socié, Gérard and Blaise, Didier and Salmenniemi, Urpu and Rambaldi, Alessandro and Gedde-Dahl, Tobias and Tholouli, Eleni and Kröger, Nicolaus and Bourhis, Jean-Henri and Von Dem Borne, Peter and Daguindau, Etienne and Forcade, Edouard and Nagler, Arnon and Esteve, Jordi and Ciceri, Fabio and Bazarbachi, Ali and Mohty, Mohamad},
title = {Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27187}
}
EUVIMED